a Sanofi company, announced today that the European Commission (EC) has
granted marketing authorization for Cerdelga® (INN:
eliglustat) capsules, a first line oral therapy for certain adults
living with Gaucher disease type 1. A small number of adult patients who...
company, today announced that the first U.S. patients have initiated
treatment with Lemtrada® (alemtuzumab) in the commercial
setting following its November 14th FDA approval for the
treatment of patients with relapsing forms of multiple sclerosis (MS...
a Sanofi company, announced today that the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency (EMA) has
adopted a positive opinion recommending approval of Cerdelga®
(eliglustat) capsules, an oral treatment for certain adults...
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO® (mipomersen sodium) injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the...